E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Severe Hemophilia-A (< 1% FVIII:C) |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060613 |
E.1.2 | Term | Hemophilia A (Factor VIII) |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10053753 |
E.1.2 | Term | Hemophilia A without inhibitors |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060612 |
E.1.2 | Term | Hemophilia A |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate efficacy and safety of BAY 81-8973 for treatment of bleeds and prophylaxis (as of Amd 8) |
|
E.2.2 | Secondary objectives of the trial |
To compare bleeding frequency of prophylactic treatment with BAY 81-8973 (dose determined byCS/EP versus dose determined by CS/ADJ) as measured by the bleeding rate •To compare in vivo recovery (IVR) at the 6 month periods based on potency determinations (CS/EP versus CS/ ADJ) during prophylactic treatment with BAY 81-8973. •To evaluate the potential for inhibitory antibody formation during prophylactic treatment with BAY 81-8973 •To evaluate the potential for antibody formation to HSP-70 and/or hamster proteins during prophylactic treatment with BAY 81-8973. •To evaluate surgical outcomes during treatment with BAY 81-8973. •To assess quality of life (QoL) and pharmaco-economic parameters during prophylactic treatment with BAY 81-8973. •To assess the safety and tolerability profile of BAY 81-8973 by assessing clinical chemistry, hematological parameters, and adverse event presentation |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male, aged 12 to 65 years • Severe hemophilia A, defined as < 1% FVIII:C as determined by one-stage clotting assay at the time of screening. If screening result turns out to be equal to or higher than 1%, then severe hemophilia A may be confirmed by one of the following (as of Amd 6): Documented historical evidence from a recognized (certified) clinical laboratory (acceptable to GCL) demonstrating < 1% FVIII:C as determined by one-stage clotting assay, or Assay results from a previous Bayer hemophilia clinical trial • ≥150 exposure days (ED) in total with any recombinant FVIII or plasma-derived FVIII only. Cryoprecipitate and fresh frozen plasma treatments are not considered in this total. (as of Amd 1) • Currently receiving on-demand or any type of prophylaxis treatment regimen with any FVIII product. • No current evidence of inhibitor antibody as measured by the Nijmegen modified Bethesda assay [<0.3 Bethesda units (BU/mL)] (as of Amd 5) in 2 consecutive samples and absence of clinical signs or symptoms of decreased response to FVIII administration. (First negative sample can be historical if obtained within 3 months prior to screening. Second negative, confirmatory sample testing must, in all cases, be performed by a central laboratory using the Nijmegen test. If a first recent sample is not available, then testing for 2 negative samples must be performed by the central laboratory at least 1 week apart). Subjects may not receive FVIII within 72 hours (as of Amd 5) prior to the collection of samples for inhibitor testing. • No history of FVIII inhibitor formation, defined as inhibitor antibody < 0.6 BU/mL, by the Bethesda assay. However, patients with a maximum historical titer of 1.0 BU (as of Amd 5) with the Classical Bethesda assay on no more than 1 occasion but with at least 3 subsequent (as of Amd 1) successive negative results (<0.6 BU) thereafter are also eligible. • Willingness and ability to complete training in the use of the study electronic patient diary (EPD) by the subject or a surrogate (a caregiver or family member over 18 years of age). (as of Amd 1) • Written informed consent by subject and parent/legal representative, if under age of consent per local regulation. |
|
E.4 | Principal exclusion criteria |
• Presence of another bleeding disease that is different from hemophilia A (e.g., von Willebrand disease, hemophilia B) • Thrombocytopenia (platelet count < 100,000/mm3) • Abnormal renal function (serum creatinine > 2.0 mg/dL) • Presence of active liver disease verified by medical history or persistent and increased alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5x the upper limit of normal (ULN) or severe liver disease as evidenced by an INR >4, hypoalbuminemia, and significant portal vein hypertension in the judgment of the Investigator. (as of Amd 5) • Received treatment with immunomodulatory agents within the last 3 months prior to study entry or requires treatment during the study. [The following drugs are allowed: interferon-α treatment for hepatitis C virus (HCV), highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV), and or a total of 2 courses of pulse treatment with steroids for a maximum of 7 days at 1 mg/kg or less]. • Absolute CD4 lymphocyte cell count <250 cells/uL (as of Amd 5) • Receiving or has received other experimental drugs within 3 months prior to study entry, with the exception of Bayer Kogenate (Bayer factor VIII study drugs) received in studies within 2 weeks prior to study entry (as of Amd 1). • Requires any pre-medication to tolerate FVIII injections (e.g., antihistamines) • Unwilling to comply with study visits or other protocol requirements or is not suitable for participation in this study for any reason, according to the Investigator • Known hypersensitivity to hamster and mouse protein. • Any subject who cannot forego at least 3 days without receiving FVIII for washout purposes. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
•To demonstrate efficacy and safety of BAY 81-8973 for treatment of bleeds and prophylaxis |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Subjects can record a bleed in their electronic diary any time during the one year study. Data analysis will occur at the end of the study. |
|
E.5.2 | Secondary end point(s) |
• To compare bleeding frequency of prophylactic treatment with BAY 81 8973 (dose determined byCS/EP versus dose determined by CS/ADJ) as measured by the bleeding rate (as of Amd 8) • To compare in vivo recovery (IVR) at the 6 month periods based on potency determinations (CS/EP versus CS/ADJ) during prophylactic treatment with BAY 81-8973. (as of Amd 1, some text deleted as of Amd 8) • To evaluate the potential for inhibitory antibody formation during prophylactic treatment with BAY 81-8973 (some text deleted as of Amd 8) • To evaluate the potential for antibody formation to HSP-70 and/or hamster proteins during prophylactic treatment with BAY 81-8973. (some text deleted as of Amd 8) • To evaluate surgical outcomes during treatment with BAY 81-8973. (as of Amd 8) • (some text deleted as of Amd 8) • To assess quality of life (QoL) and pharmaco-economic parameters during prophylactic treatment with BAY 81-8973. • To assess the safety and tolerability profile of BAY 81-8973 by assessing clinical chemistry, hematological parameters, and adverse event presentation (as of Amd 1).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Patient data will be collected throughout the study and analyzed at the end of the study. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Comparing different doses of the same study drug: BAY 81-8973 (~18% difference between 2 doses). |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 13 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Austria |
Denmark |
Germany |
Israel |
Italy |
Norway |
Poland |
South Africa |
Spain |
Sweden |
Turkey |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Visit 7 is the last study visit. Patients will receive one final Follow-Up Phone Call (1-2 weeks after Visit 7 or end of treatment). Completion of follow-up phone calls for all patients will be considered “end of trial” |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |